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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The primary objectives are to evaluate the efficacy and safety of probiotics for the management of IBS, abdominal migraine and
functional abdominal pain in children.
B A C K G R O U N D
Description of the condition
‘Functional abdominal pain’ is pain occurring in the abdomen that
is not associated with any visible or detectable pathology. This rep-
resents a number of conditions and can be continuous or sporadic
(recurrent). Although the exact cause is not identified, nervous
signalling from the brain or chemicals from the gut may cause the
bowel to be more sensitive to factors that normally do not cause
pain (examples include gaseous distention or bowel stretching).
Because of this change in bowel function associated with this type
of pain, this is often referred to as functional abdominal pain.
The prevalence of childhood Irritable bowel syndrome (IBS) in
the United States has been shown to be approximately 2.9% (Saps
2012), compared to a prevalence of 9.3% for childhood abdominal
migraine and 0.3% for childhood functional abdominal pain (Van
Tilburg 2014). Functional abdominal pain disorders are extremely
common in paediatric patients seen by gastroenterologists. In fact,
almost 25% of children assessed for bowel problems are diagnosed
with functional abdominal pain (Williams 1996).
The diagnosis of functional abdominal pain in childrenhas evolved
with time,most noticeably through thework of theROMEIII pro-
cess that led to the recognition of a group of ’abdominal pain-re-
lated functional gastrointestinal disorders’ (Rasquin 2006). More
recently, the Rome IV process has updated this to ’functional ab-
dominal pain disorders’ (Hyams 2016). Rome III notes that the
term functional abdominal pain was used generically and inter-
changeably to refer to the whole group of abdominal pain-related
problems and this clarification particularly has impact for research
purposes.
The current categorization of functional abdominal pain includes:
IBS, abdominal migraine and functional abdominal pain. Func-
tional dyspepsia is not included in this category as this condi-
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tion includes a different set of symptoms, treatments, and a much
more discrete presentation than the other three conditions (Hyams
2016).
The diagnosis of IBS must include all of the following:
1. Abdominal pain at least four days per month associated with
one or more of the following:
a. Related to defecation;
b. A change in frequency of stool; and
c. A change in form (appearance) of stool.
2. In children with constipation, the pain does not resolve with
resolution of the constipation (children in whom the pain resolves
have functional constipation, not IBS).
3. After appropriate evaluation, the symptoms cannot be fully
explained by another medical condition.
These criteria should be fulfilled for the last three months with
symptom onset at least six months before diagnosis of IBS.
The diagnosis of abdominal migraine must include all of the fol-
lowing:
1. Paroxysmal episodes of intense, acute periumbilical, midline or
diffuse abdominal pain lasting one hour or more (should be the
most severe and distressing symptom);
2. Episodes are separated by periods of usual health lasting weeks
to months;
3. The pain is incapacitating and interferes with normal activities;
4. Stereotypical pattern and symptoms in the individual patient;
5. The pain is associated with 2 or more of the following:
a. Anorexia;
b. Nausea;
c. Vomiting;
d. Headache;
e. Photophobia;
f. Pallor; and
6. After appropriate evaluation, the symptoms cannot be fully
explained by another medical condition.
These criteria should be fulfilled two or more times in the past 12
months.
The diagnosis of functional abdominal pain must include all of
the following:
1. Episodic or continuous abdominal pain that does not occur
solely during physiologic events (e.g. eating, menses);
2. Insufficient criteria for IBS, functional dyspepsia, or abdominal
migraine;
3. After appropriate evaluation, the abdominal pain cannot be
fully explained by another medical condition.
These criteria should be met at least once per week for at least two
months prior to diagnosis.
Description of the intervention
Probiotics are microorganisms that, when ingested, are thought
to have beneficial effects on a person’s health. Research is ongoing
into the use of probiotics for the treatment of various gastroin-
testinal illnesses including inflammatory pathological disorders,
functional disorders, and chronic non-pathological disorders. In
infants, it has been proposed that supplying probiotic bacteria can
redress the balance of intestinal bacteria and provide a healthier
intestinal microbiota landscape with resulting impact on transit
through the gut (Savino 2013). In the context of constipation,
these mechanisms have been proposed to enhance colonic peri-
stalsis and shorten whole gut transit time (Waller 2011).
How the intervention might work
The use of microorganisms might change the composition bacte-
rial colonies in the bowel and reduce inflammation, as well as pro-
moting normal gut physiology and thereby reducing functional
symptoms. Some probiotics may influence colonic motility by
softening the stool, changing secretion and absorption of water
and electrolytes, modifying smooth muscle cell contractions, in-
creasing the production of lactate and short-chain fatty acids, and
lowering intraluminal pH (Waller 2011). Additionally, as essen-
tially a food supplement, probiotics are generally perceived as hav-
ing a good safety profile, particularly when compared with other
treatments.
Why it is important to do this review
As interest in probiotics for the treatment of gastrointestinal disor-
ders is relatively new, until recently there has been a general paucity
of research on the use of these agents. In the context of functional
abdominal pain, a previous Cochrane review found only three
studies examining probiotics (Huertas-Ceballos 2009). It must be
noted that as Huertas-Ceballos 2009 considered several dietary
interventions, the search strategy was not focused on probiotics.
Additionally, more contemporaneous studies have now been pub-
lished (Francavilla 2010; Romano 2010).With this recent increase
in published studies, a new and focused synthesis of the evidence
using the Cochrane Collaboration approach is needed.
O B J E C T I V E S
The primary objectives are to evaluate the efficacy and safety of
probiotics for the management of IBS, abdominal migraine and
functional abdominal pain in children.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs) will be considered for inclu-
sion.
Types of participants
Participants will include children between 4 and 18 years of age
with a diagnosis of functional abdominal pain disorder. Partici-
pants could include children with IBS, abdominal migraine and
functional abdominal pain as defined by Rome IV criteria (Hyams
2016). This is in line with the Rome IV criteria which do not
cover infants or toddlers. A separate set of diagnostic criteria ad-
dress this group (Hyams 2016). Participants who meet earlier
Rome criteria will also be included. Studies including children
with Hirschsprung’s disease, previous bowel surgery or complex
congenital disorders will not be included.
Types of interventions
Studies that assess probiotic preparations in any form (powder,
liquid, capsule) through any route (either oral or rectal) as a sin-
gle species or as a cocktail of multiple species or treatments (for
example, symbiotic) compared to placebo, no treatment or any
other interventional preparation will be considered for inclusion.
Studies with probiotics as adjunct therapy will also be considered
for inclusion.
Types of outcome measures
Primary outcomes
The primary outcomes measures considered will be:
a. Global improvement or treatment success as defined by primary
studies;
b. Severity of pain or change in severity of pain; and
c. Frequency of pain or change in frequency of pain.
Secondary outcomes
Secondary outcomes will include:
a. Serious adverse events;
b. Withdrawal due to adverse events;
c. Adverse events;
d. School performance or change in school performance or atten-
dance;
e. Social and psychological functioning or change in social and
psychological functioning; and
f. Quality of life or change in quality life measured using any
validated measurement tool.
Search methods for identification of studies
Electronic searches
Electronic Resources
Wewill identify relevant trials by searching the following electronic
sources:
1. PubMed (from inception to present);
2. MEDLINE (from inception to present);
3. EMBASE (from inception to present);
4. CENTRAL; and
5. The Cochrane IBD Group Specialized Trials Register.
The search strategies are shown in Appendix 1. We will not re-
strict the searches by date or language. Studies published in a non-
English language will be professionally translated in full.
Searching other resources
Reference Searching
We will search the references of all included studies and relevant
systematic reviews to identify studies missed by the search strate-
gies.
Personal contacts
Wewill contact leaders in the field to try and identify other relevant
studies.
Manufacturers
Manufacturers of probiotic agents will be contacted to try and
identify other studies.
Trial Registries
We will also search clinicaltrials.gov and the WHO Trials portal
(ICTRP) to identify ongoing studies.
Grey Literature
We will search Google, Google Scholar and the OpenGrey Repos-
itory using themain search terms.We will hand-search conference
proceedings fromDigestive Disease Week, United European Gas-
troenterology Week and the European Society for Paediatric Gas-
troenterology, Hepatology and Nutrition annual scientific meet-
ing from the past two years to identify other potentially relevant
studies that may not be published in full. Concerns have been
raised regarding the accuracy of data reported in abstract publi-
cations (Pitkin 1999). Therefore, where references to relevant un-
published or ongoing studies are identified, we will make attempts
to collect sufficient extra information to allow inclusion in this
systematic review. Studies from the grey literature will only be in-
cluded if sufficient data are reported to judge eligibility for inclu-
sion. If data are incomplete, we will contact the study authors in
order to verify the eligibility of the study and we will only include
the study if suitable data to assess quality and outcomes are sup-
plied.
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Data collection and analysis
Selection of studies
Two authors (CW and MG) will independently screen titles, ab-
stracts, and full reports for eligibility against the inclusion criteria.
Specifically, they will:
· Collate the search results using reference management software
and remove any duplicate records;
· Examine titles and abstracts to remove results that are not rele-
vant;
· Retrieve full texts of potentially relevant reports;
· Link together multiple report that are found for the same study;
· Examine full text reports for studies that meet the inclusion
criteria;
· Correspond with primary study investigators, to clarify study
eligibility when needed; and
· At all stages, the authors will record reasons for inclusion and
exclusion of studies, resolving any disagreements through reaching
consensus. When consensus cannot be reached, we will consult
with a third author (AA).
Data extraction and management
We will develop data extraction forms a priori to extract infor-
mation on relevant features and results of included studies. Two
authors (CW andMG) will independently extract and record data
on a predefined checklist. Extracted data will include the following
items:
· Characteristics of patients (age, gender, disease distribution, dis-
ease duration, activity index);
. Inclusion and exclusion criteria of studies;
· Total number of patients originally assigned to each intervention
group;
· Intervention: type and amount of probiotics;
· Control: no intervention, placebo or other interventions;
· Concurrent medications; and
·Outcomes: time of assessment, length of follow-up, type of symp-
tom score used, and adverse events.
Assessment of risk of bias in included studies
Two review authors (CW and MG) will independently assess the
risk of bias of included studies using the Cochrane risk of bias tool
(Higgins 2011a).We will assess the following items: sequence gen-
eration; allocation concealment; blinding of participants, parents
and health professionals; blinding of outcome assessment; incom-
plete outcome data; selective outcome reporting; and other poten-
tial threats to validity.We will judge each domain as being at ’low’,
’high’, or ’unclear’ risk of bias. We will compare the judgments
and discuss and resolve any inconsistencies in the assessments. A
third review author (AA) will resolve any disagreements.
Sequence generation for randomisation
We will only consider RCTs for inclusion in the review. We will
assess randomisation as being at low risk of bias where the proce-
dure for random sequence generation was explicitly described. Ex-
amples include computer-generated random numbers, a random
numbers table, or coin-tossing. Where no description is given, we
will contact the authors for further information.
Allocation concealment
We will assess concealment of treatment allocation as being at low
risk of bias if the procedure was explicitly described and adequate
efforts weremade to ensure that intervention allocations could not
have been foreseen in advance of, or during, enrolment. Examples
include centralised randomisation, numbered or coded containers,
or sealed envelopes. Procedures considered to have a high risk of
bias include alternation or reference to case record numbers or
dates of birth. Where no description was given of the method of
allocation concealment, we will contact the study authors and,
where we don’t receive a response, we will assign a judgment of
unclear risk of bias.
Blinding of participants, parents and health professionals
In this context, the intervention is administered by parents as well
as directly by children, so in effect, we will consider them both
the targets of the blinding procedures. We will primarily assess the
risk of bias associated with the blinding of participants based on
the likelihood that such blinding is sufficient to ensure they had
no knowledge of which intervention they received. We will note
the blinding of health professionals if reported.
Blinding of outcome assessment
For each included study, we will describe the methods used, if
any, to blind the outcome assessors from knowledge of which
intervention a participant received. We will judge studies to be at
low risk of bias if outcome assessors blinded, or where we consider
that the lack of blinding could not have affected the results. If
blinding was not done or was not possible because of the nature
of the intervention, we will judge the study to be at high risk of
bias because it is possible that the lack of blinding influenced the
results. If no description is given, we will contact the study authors
for more information, and if we do not receive a response, we will
assign a judgment of unclear risk of bias.
Incomplete outcome data
Incomplete outcome data essentially includes attrition, exclusions,
and missing data.
We will assign a judgment of low risk of bias in the following
instances:
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1. If participants included in the analysis are exactly those who
were randomised into the trial; missing outcome data are
balanced in terms of numbers across intervention groups, with
similar reasons for missing data across groups; or if there are no
missing outcome data;
2. If for dichotomous outcome data, the proportion of
missing outcomes compared with observed event risk is not
sufficient to have a clinically relevant impact on the intervention
effect estimate;
3. If for continuous outcome data, the plausible effect size
(mean difference) among missing outcomes is not sufficient to
have a clinically relevant impact on observed effect size; or
4. If missing data have been imputed using appropriate
methods.
We will assign a judgment of high risk of bias in the following
instances:
1. When reasons for missing outcome data are likely to be
related to the true outcome, with either an imbalance in
numbers or reasons for missing data across intervention groups;
2. When for dichotomous outcome data, the proportion of
missing outcomes compared with the observed event risk is
sufficient to induce clinically relevant bias in the intervention
effect estimate;
3. When for continuous outcome data, the plausible effect size
(mean difference) among missing outcomes is sufficient to
induce clinically relevant bias in the observed effect size;
4. When an ’as-treated’ analysis is carried out in cases where
there is a substantial departure of the intervention received from
that assigned at randomisation; or
5. When there is a potentially inappropriate application of
simple imputation.
We will assign a judgment of unclear risk of bias in the following
instances:
1. When there is insufficient reporting of attrition or
exclusions, or both, to permit a judgment of low or high risk of
bias;
2. When the study reported incomplete outcome data; or
3. When the trial did not clearly report the numbers
randomised to intervention and control groups.
Selective outcome reporting
We will assess the reporting of outcomes as being at low risk of
bias if all outcomes pre-specified in the study protocol are reported
in the study manuscript or secondary publications. If no protocol
exists we will assign a rating of low risk of bias if the authors report
on the outcomes described in the methods section of the study
manuscript. We will evaluate all study publications (primary and
secondary) to ensure that there is no evidence of selective outcome
reporting. If no description is given, we will contact the authors
for more information, and if we do not receive a response, we will
assign a judgment of unclear risk of bias. If there is evidence of se-
lective reporting (deviation from protocol, key planned outcomes
not reported), we will assign a judgment of high risk of bias.
Other potential threats to validity
Wewill consider other potential sources of bias including early trial
termination (e.g. if a study was stopped early due to a data-depen-
dent process) and baseline imbalance between treatment groups.
We will assess the study as being at low risk of bias if it appears to
be free from such threats to validity. When the risk of bias is un-
clear from the published information, we will attempt to contact
the study authors for clarification. If this is not forthcoming, we
will assess these studies as being at unclear risk of bias.
GRADE and ’Summary of findings’ tables
We will assess the overall quality of evidence supporting the pri-
mary outcomes (i.e. global improvement or treatment success,
severity of pain and frequency of pain) and selected secondary
outcomes (adverse events, serious adverse events and withdrawal
due to adverse events) using the GRADE approach (Guyatt 2008;
Schünemann 2011). The GRADE approach appraises the quality
of a body of evidence based on the extent to which one can be
confident that an estimate of effect, or association, reflects the item
being assessed. RCTs start as high-quality evidence, but may be
downgraded due to risk of bias (methodological quality), indirect-
ness of evidence, unexplained heterogeneity, imprecision (sparse
data), and publication bias. Two review authors (CW and MG)
will independently assess the overall quality of the evidence for
each outcome after considering each of these factors and grade
them as follows:
1. high quality: further research is very unlikely to change
confidence in the estimate of effect;
2. moderate quality: further research is likely to have an
important impact on confidence in the estimate of effect, and
may change the estimate;
3. low quality: further research is very likely to have an
important impact on confidence in the estimate of effect, and is
likely to change the estimate; or
4. very low quality: any estimate of effect is very uncertain.
Measures of treatment effect
Dichotomous outcomes
For dichotomous outcomes, we will calculate the risk ratio (RR)
and corresponding 95% confidence interval (95%CI).
Continuous outcomes
For continuous outcomes, we will calculate the mean difference
(MD) and corresponding 95% CI.
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Unit of analysis issues
Where cross-over trials are included, we will extract data from the
first phase of the study (i.e. before the cross-over occurred). We
will conduct separate analyses for comparisons between probiotics
versus placebo, and probiotics versus active comparator (e.g. lactu-
lose). To deal with repeated observations on participants, we will
determine appropriate fixed intervals for follow-up for each out-
come. To deal with events that may re-occur (e.g. adverse events),
we will report on the proportion of participants who experience
at least one event. If we encounter multiple treatment groups (e.g.
different probiotic dose groups or different probiotic species), we
will divide the placebo group across the treatment groups or we
will combine probiotic groups to create a single pair-wise compar-
ison as appropriate.
Dealing with missing data
Where data are missing, we will contact the corresponding au-
thors of included studies to supply any unreported data. For all
outcomes in all studies, we will carry out analyses as far as possible
on an intention-to-treat (ITT) basis; that is, we will attempt to
include all participants randomised to each group in the analyses,
and we will analyse all participants in the group to which theywere
allocated regardless of whether or not they received the allocated
intervention. For missing continuous data, we will estimate stan-
dard deviations from other available data, such as standard errors,
or we will impute them using the methods suggested in Higgins
2011b. We will conduct analyses for continuous outcomes based
on participants completing the trial, in line with available case
analysis; this will assume that data are missing at random. If there
is a discrepancy between the number randomised and the number
analysed in each treatment group, we will calculate and report the
percentage lost to follow-up in each group. When it is not possible
to obtain missing data, we will record this in the data collection
form, report it in the ’Risk of bias’ table, and discuss the extent
to which the missing data could alter the results and hence the
conclusions of the review. We will conduct sensitivity analyses to
explore the impact of including studies with high levels of missing
data on the overall estimate of treatment effect.
Assessment of heterogeneity
Heterogeneity among trial results will be assessed by visual inspec-
tion of forest plots and by calculating the Chi2 test (a P value of
0.10 is regarded as statistically significant heterogeneity). We will
also use the I2 statistic to quantity the effect of heterogeneity (
Higgins 2003). We will conduct sensitivity analyses as appropri-
ate to investigate heterogeneity. For example, if a pooled analysis
shows statistically significant heterogeneity and a visual inspection
of the forest plot identifies studies that may have contributed to
this heterogeneity, the analysis will be repeated excluding these
studies to see if this explains the heterogeneity.
Assessment of reporting biases
If an appropriate number of studies are pooled for meta-analysis
(> 10 studies), we plan to investigate the possibility of publication
bias through the construction of funnel plots (trial effects versus
trial size).
Data synthesis
Data from individual trials will be combined for meta-analysis
when the interventions, patient groups and outcomes are deemed
to be sufficiently similar (determined by consensus). We will cal-
culate the pooled RR and corresponding 95%CI for dichotomous
outcomes. We will calculate the pooled MD and corresponding
95% CI for continuous outcomes that were measured using the
same units. We will calculate the pooled standardised mean differ-
ence (SMD) and 95% CI when different scales are used to mea-
sure the same underlying construct evaluate the same underlying
construct. Meta-analysis will be carried out using a random-effects
model. The Cochrane Collaboration review manager (RevMan)
software will be used for data analysis. Data will be analysed ac-
cording to ITT principle. Patients with final missing outcomes
will be assumed to be treatment failures. Analyses will be grouped
by length of follow-up. Data will not to be pooled for meta-anal-
ysis if a high degree of heterogeneity is detected (i.e. I2 > 75%).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be carried out to further study the effects
of a number of variables on the outcomes including:
a. Specific probiotic preparation or species;
b. Probiotic dose;
c. Length of therapy, follow-up;
d. Specifically what, if any agents, were initially allowed in the
protocol to clear any impaction (such as enemas);
e. Whether the probiotic was sole therapy or adjunct therapy; and
f. Type of functional pain disorder (i.e. IBS, abdominalmigraine or
functional abdominal pain, in line with Rome IV criteria (Hyams
2016)).
Sensitivity analysis
Sensitivity analyses will be conducted based on the following:
a. Dropouts and exclusions, by conducting worst-case versus best-
case scenario analyses;
b. Random-effects versus fixed-effect models;
c. Studies published in full versus abstract; and
d. Removing studies judged to be at high risk of bias.
A C K N OW L E D G E M E N T S
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Partial funding for the Cochrane IBD Group (April 1, 2016 -
March 31, 2018) has been provided byCrohn’s andColitis Canada
(CCC).
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A P P E N D I C E S
Appendix 1. Sample search strategy
EMBASE
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross over$ or cross-over$).mp.
4. placebo$.mp.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
10. (tripl$ adj blind$).mp.
11. assign$.mp.
12. allocat$.mp.
13. crossover procedure/
14. double blind procedure/
15. single blind procedure/
16. triple blind procedure/
17. randomized controlled trial/
18. or/1-17
19. exp Probiotics/
20. exp Synbiotics/
21. probiotic*.tw.
22. synbiotic*.tw.
23. exp Lactobacillus/
24. lactobacill*.tw.
25. bacill*.tw.
26. exp Bifidobacterium/
27. (bifidus or bifidobacter*).tw.
28. exp Streptococcus thermophilus/
29. streptococcus thermophilus.tw.
30. streptococc*.tw.
31. exp Lactococcus/
32. lactococc*.tw.
33. Bacillus subtilis/
34. bacillus subtilis.tw.
35. exp Enterococcus/
36. exp Enterococcus faecium/ or Enterococcus faecalis/
37. exp Saccharomyces/
38. saccharomyc*.tw.
39. leuconostoc.tw.
40. pediococc*.tw.
41. bulgarian bacillus.tw.
42. (beneficial adj3 bacter*).tw.
43. (Escherichia coli or “E. coli”).tw.
44. Yeast.tw.
45. (fungus or fungi).tw.
46. (VSL# 3 or VSL 3).tw.
47. or/19-46
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48. (abdominal pain or FAPS).tw.
49. Functional abdominal.tw.
50. Bowel pain.tw.
51. Bowel discomfort.tw.
52. Stomach pain.tw.
53. Stomach discomfort.tw.
54. (chronic functional abdominal pain or CFAP).tw.
55. exp irritable bowel syndrome/
56. (irritable bowel or IBS).tw.
57. functional dyspepsia.tw.
58. abdominal migraine.tw.
59. or/48-58
60. 18 and 47 and 59
MEDLINE
1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross over$ or cross-over$).mp.
4. placebo$.mp.
5. single blind.mp.
6. double blind.mp.
7. triple blind.mp.
8. (singl$ adj blind$).mp.
9. (double$ adj blind$).mp.
10. (tripl$ adj blind$).mp.
11. assign$.mp.
12. allocat$.mp.
13. randomized controlled trial/
14. or/1-13
15. exp Probiotics/
16. exp Synbiotics/
17. probiotic*.tw.
18. synbiotic*.tw.
19. exp Lactobacillus/
20. lactobacill*.tw.
21. bacill*.tw.
22. exp Bifidobacterium/
23. (bifidus or bifidobacter*).tw.
24. exp Streptococcus thermophilus/
25. streptococcus thermophilus.tw.
26. streptococc*.tw.
27. exp Lactococcus/
28. lactococc*.tw.
29. Bacillus subtilis/
30. bacillus subtilis.tw.
31. exp Enterococcus/
32. exp Enterococcus faecium/ or Enterococcus faecalis/
33. exp Saccharomyces/
34. saccharomyc*.tw.
35. leuconostoc.tw.
36. pediococc*.tw.
37. bulgarian bacillus.tw.
38. (beneficial adj3 bacter*).tw.
39. (Escherichia coli or “E. coli”).tw.
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40. Yeast.tw.
41. (fungus or fungi).tw.
42. (VSL# 3 or VSL 3).tw.
43. or/15-42
44. (abdominal pain or FAPS).tw.
45. Functional abdominal.tw.
46. Bowel pain.tw.
47. Bowel discomfort.tw.
48. Stomach pain.tw.
49. Stomach discomfort.tw.
50. (chronic functional abdominal pain or CFAP).tw.
51. exp irritable bowel syndrome/
52. (irritable bowel or IBS).tw.
53. functional dyspepsia.tw.
54. abdominal migraine.tw.
55. or/44-54
56. 14 and 43 and 55
COCHRANE LIBRARY
#1 MeSH descriptor: [Probiotics] explode all trees
#2 MeSH descriptor: [Synbiotics] explode all trees
#3 probiotic*
#4 synbiotic*
#5 MeSH descriptor: [Lactobacillus] explode all trees
#6 lactobacill*
#7 bacill*
#8 MeSH descriptor: [Bifidobacterium] explode all trees
#9 (bifidus or bifidobacter*)
#10 MeSH descriptor: [Streptococcaceae thermophilus] explode all trees
#11 streptococcus thermophilus
#12 streptococc*
#13 MeSH descriptor: [Lactococcus] explode all trees
#14 lactococc*
#15 MeSH descriptor: [Bacillus subtilis] explode all trees
#16 bacillus subtilis
#17 MeSH descriptor: [Enterococcus] explode all trees
#18 enterococcus faec*
#19 MeSH descriptor: [Saccharomyces] explode all trees
#20 saccharomyc*
#21 leuconostoc*
#22 pediococc*
#23 bulgarian bacillus
#24 (Escherichia coli or “E. coli”).tw.
#25 Yeast.tw.
#26 (fungus or fungi).tw.
#27 (#1 or #2 or #3 or #4 of #5 or #6 or #7 or #8 or #9 or #10 or #11 of #12 or #13 or #14 or #15 or #16 or #17 of #18 or #19 or #
20 or #21 or #22 or #23 or #24 or #25 or #26)
#28 functional abdominal pain or “FAPS”
#29 chronic functional abdominal pain or “CFAP”
#30 MeSH descriptor: [Irritable Bowel Syndrome] explode all trees
#31 irritable bowel or “IBS”
#32 functional dyspepsia
#33 abdominal migraine
#34 #28 or #29 or #30 or #31 or #32 or #33
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#35 #27 and #34
CINAHL
1. (TI probiotic* or AB probiotic*) OR (TI synbiotic* or AB synbiotic*) OR (TI probiotics* or AB probiotics*) OR (TI lactobacill*
or AB lactobacill*) OR (TI bacill* or AB bacill*) OR (TI bifidobacter* or AB bifidobacter*) OR (TI bifidus* or AB bifidus*) OR
(TI streptococc* or AB streptococc*) OR (TI lactococc* or AB lactococc*) OR (TI enterococcus* or AB enterococcus*) OR (TI
saccharomyc* or AB saccharomyc*) OR (TI leuconostoc* or AB leuconostoc*) OR (TI pediococc* or AB pediococc*) OR (TI *coli or
AB *coli) OR (TI yeast* or AB yeast*) OR (TI fung* or AB fung*) OR (TI VSL* or AB VSL*)
2. (TI abdominal pain* or AB abdominal pain*) OR (TI functional abdominal* or AB functional abdominal *) OR (TI bowel pain*
or AB bowel pain*) OR (TI bowel discomfort* or AB bowel discomfort*) OR (TI stomach pain* or AB stomach pain*) OR (TI
stomach discomfort* or AB stomach discomfort*) OR (TI FAPS or AB FAPS) OR (TI CFAP or AB CFAP) OR (TI chronic functional
abdominal pain or AB chronic functional abdominal pain) OR (TI irritable bowel* or AB irritable bowel*) OR (TI IBSor AB IBS*)
OR (TI functional dyspepsia or AB functional dyspepsia) OR (TI abdominal migraine* or AB abdominal migraine*)
3. 1 AND 2
PsycInfo
ti(probiotic*OR synbiotic*OR lactobacill*ORbacill*ORbifidobacter*ORbifidus*ORstreptococc*OR lactococc*ORenterococcus*
OR saccharomyc* OR leuconostoc* OR pediococc* OR *coli OR yeast* OR fung* OR VSL*) AND ti(abdominal pain OR functional
abdominalORbowel painORbowel discomfortOR stomach painOR stomach discomfortORFAPSORCFAPORchronic functional
abdominal pain OR irritable bowel* OR IBS OR functional dyspepsia OR abdominal migraine)
clinical trials.gov
conditions: abdominal pain OR functional abdominal OR bowel pain OR bowel discomfort OR stomach pain OR stomach discomfort
OR FAPS OR CFAP OR chronic functional abdominal pain OR irritable bowel* OR IBS OR functional dyspepsia OR abdominal
migraine
interventions: probiotic OR synbiotic OR lactobacill OR bacill OR bifidobacter OR bifidus OR streptococc OR lactococc OR
enterococcus OR saccharomyc OR leuconostoc OR pediococc OR coli OR yeast OR fung OR VSL
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